Skip to main content


Latest articles

17-06-2019 | Oncology | News | Article

Bevacizumab adds no value to chemotherapy for metastatic urothelial cancer

Adding bevacizumab to gemcitabine plus cisplatin chemotherapy does not improve overall survival when used as first-line therapy for metastatic urothelial carcinoma, show results of the phase III CALGB 90601 study.

23-05-2019 | Oncology | News | Article

Sustained nivolumab, ipilimumab activity shown in advanced urothelial cancer

Extended follow-up of patients with unresectable locally advanced or metastatic urothelial carcinoma in the CheckMate 032 trial shows sustained antitumor activity of nivolumab alone and in combination with ipilimumab.

09-05-2019 | Oncology | News | Article

5α-reductase inhibitors linked to elevated prostate cancer death rates

Use of 5α-reductase inhibitors, typically for benign prostatic hyperplasia, may delay prostate cancer diagnosis and thus increase mortality risk, show results of a large population-based cohort study.

29-04-2019 | Oncology | News | Article

FDA approves first-line pembrolizumab–axitinib for advanced RCC

Click through to read more

26-04-2019 | Oncology | News | Article

Erdafitinib Approved For Advanced Urothelial Carcinoma

Read more on this FDA announcement here

21-03-2019 | Oncology | News | Article

Second-line atezolizumab feasible for advanced urothelial carcinoma with comorbidity

Results from the SAUL study add support for the use of atezolizumab in patients with advanced urothelial or nonurothelial carcinoma of the urinary tract, including those with autoimmune disease and other comorbidities.

27-07-2018 | Prostate cancer | News | Article

Robot-assisted laparoscopy meets open radical prostatectomy for functional outcomes

Phase III trial findings suggest that men who require radical prostatectomy for localised prostate cancer achieve similar functional outcomes at 2 years, regardless of whether they undergo robot-assisted laparoscopic surgery or an open radical retropubic procedure.

08-03-2018 | Genitourinary cancer | News | Article

DNA damage response and repair gene defects linked to PD-1 pathway blockade response

In patients with metastatic urothelial carcinoma treated with agents targeting programmed cell death protein 1 or its ligand, the presence of alterations in tumoral DNA damage response and repair genes is associated with better outcomes, findings indicate.

12-09-2017 | Oncology | News | Article

Ramucirumab plus docetaxel prolongs PFS in advanced urothelial cancers

Adding ramucirumab to docetaxel significantly improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy, show results from the phase III RANGE trial.

14-06-2017 | Oncology | News | Article

First-line pembrolizumab feasible for cisplatin-ineligible advanced urothelial cancer patients

Advanced urothelial carcinoma patients who are unsuitable for platinum-based chemotherapy could benefit from first-line pembrolizumab, suggest phase II results reported at the American Society of Clinical Oncology 2017 annual meeting in Chicago, Illinois, USA.

13-06-2017 | Oncology | News | Article

Pembrolizumab after recurrence recommended for advanced urothelial carcinoma

A prespecified third analysis has confirmed initial findings of the KEYNOTE-045 trial of pembrolizumab in patients with advanced urothelial carcinoma who have progressed after platinum-based chemotherapy.

12-06-2017 | Oncology | Main feed | News

Electronic PRO symptom monitoring benefits revealed

Using an electronic patient-reported outcomes system improves overall survival and offers other clinical benefits for patients undergoing chemotherapy for metastatic solid tumors, research suggests.

06-06-2017 | Oncology | Main feed | News

Low testosterone risk flagged for testicular cancer survivors

Clinicians should be aware of the risk of hypogonadism in men who have been treated for testicular cancer, highlight findings from The Platinum Study.

16-05-2017 | Non-small-cell lung cancer | News | Article

Avelumab, pembrolizumab indications expanded

Click through to read more on these announcements

08-05-2017 | Oncology | News | Article

Brigatinib, durvalumab given FDA approval for new indications

Click through to read more on these announcements

24-08-2016 | Prostate cancer | News | Article

ADT not recommended for favourable-risk African–American prostate cancer patients

Exposure to even a short course of neoadjuvant androgen-deprivation therapy has a deleterious effect on survival in African–American men with favourable-risk prostate cancer.

10-08-2016 | Oncology | News | Article

Afatinib active in ERBB3, HER2-altered metastatic urothelial carcinoma

Patients with platinum-refractory, metastatic urothelial carcinoma harbouring ERBB3 and HER2 alterations could benefit from treatment with afatinib, which targets the ErbB family of enzymes.

17-06-2016 | Kidney cancer | News | Article

Cabozantinib extends advanced RCC overall survival

Patients with advanced or metastatic renal cell carcinoma derive a significant overall survival benefit from second-line treatment with the multi-tyrosine kinase inhibitor cabozantinib relative to everolimus.

17-06-2016 | Oncology | News | Article

ERCC2 validated as chemotherapy response biomarker in bladder cancer

Somatic mutations in the helicase-encoding ERCC2 gene are associated with response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive urothelial bladder carcinoma.

05-04-2016 | Oncology | News | Article

Elevated bladder cancer risk with pioglitazone use

Use of the antidiabetic drug pioglitazone is linked to an increased risk of developing bladder cancer, with the risk rising with increasing duration of use and dose, say Canadian researchers.

Image Credits